Table 1 The clinical characteristics, pathological characteristics and follow-up outcomes of the patients included in the training set
| Â | Group | Number (n, %) | Total |
|---|---|---|---|
Database | TCGA | 475 (45.5%) | Â |
| Â | cBioPortal | 222 (21.2%) | Â |
| Â | GEO | 348 (33.3%) | 1045 |
Age | ≤ 65 | 508 (48.6%) |  |
| Â | >65 | 352 (33.7%) | 860 |
Gleason score | 4–6 | 157 (15.0%) |  |
|  | 7–8 | 669 (64.0%) |  |
|  | 9–10 | 217 (20.8%) | 1043 |
PSA value | 4<PSA ≤ 10 | 148 (14.2%) |  |
(ng/ml) | 10<PSA ≤ 20 | 145 (13.9%) |  |
| Â | PSA>20 | 151 (14.4%) | 444 |
T stage | T1 | 140 (13.4%) | Â |
| Â | T2 | 404 (38.7%) | Â |
| Â | T3 | 451 (43.2%) | Â |
| Â | T4 | 17 (1.6%) | 1012 |
M stage | M0 | 458 (43.8%) | Â |
| Â | M1 | 2 (0.2%) | 460 |
N stage | N0 | 347 (33.2%) | Â |
| Â | N1 | 74 (7.1%) | 421 |
Survival status | Recurrence | 282 (27.0%) | Â |
(DFS) | No recurrence | 763 (73.0%) | 1045 |